BFM
CCCC icon

Boothbay Fund Management’s C4 Therapeutics CCCC Stock Holding History

Boothbay Fund Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,400
Closed -$75.7K – 1600
2023
Q4 		$75.7K Buy
+13,400
New +$30.6K ﹤0.01% 1470
2021
Q2 		– Sell
-12,026
Closed -$445K – 1871
2021
Q1 		$445K Sell
12,026
-4,178
-26% -$166K 0.02% 997
2020
Q4 		$537K Buy
+16,204
New +$470K 0.02% 717

Other funds holding CCCC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boothbay Fund Management's CCCC Position: Q1 2024 in Review

Boothbay Fund Management sold out of C4 Therapeutics (CCCC) in Q1 2024, closing a stake of 13,400 shares — an estimated $75.7K sold.

Boothbay Fund Management first reported a position in CCCC in Q4 2020 and held it in 3 quarters. The position peaked at $537K in Q4 2020. 106 funds tracked by Wall St. Rank hold CCCC as of Q1 2024.

  • Boothbay Fund Management reported no remaining C4 Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 13,400 C4 Therapeutics shares in Q1 2024, an estimated $75.7K.
  • Boothbay Fund Management first reported a position in C4 Therapeutics in Q4 2020 and held it in 3 quarters.
  • Boothbay Fund Management's C4 Therapeutics position peaked at $537K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.